Inari Medical Q1 2023 Earnings Report

Inari Medical EPS Results

• Actual EPS: -$0.04
• Consensus EPS: -$0.23
• Beat/Miss: Beat by +$0.19
• One Year Ago EPS: -$0.06

Inari Medical Revenue Results

• Actual Revenue: $116.17 million
• Expected Revenue: $110.30 million
• Beat/Miss: Beat by +$5.87 million
• YoY Revenue Growth: +33.90%

Inari Medical Announcement Details

• Quarter: Q1 2023
• Date: 5/3/2023
• Time: After Market Closes

Inari Medical (NASDAQ:NARI) builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.